▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Viridian Therapeutics (NASDAQ: VRDN)

$21.36

(-1.0%)

-$0.22

Price as of October 1, 2025, 3:58 p.m. ET

Viridian Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
VRDN	-9.91%	+91.65%	+13.89%	-88%
S&P	+17.56%	+100.43%	+14.92%	+187%

Viridian Therapeutics Company Info

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

News & Analysis

Featured Article

Viridian (VRDN) Q2 Net Loss Widens 55%

Motley Fool Markets Team | Aug 6, 2025

Featured Article

Why Shares of Viridian Therapeutics Are Falling Tuesday

The company announced preliminary trial results for its lead therapy.

James Halley | Jul 11, 2023

Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning

Dan Caplinger | Jul 11, 2023

Broader markets seemed likely to start out on a positive note despite these two outliers.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services